Sunday, 15 November 2026

What happens in the brain when cannabis makes you anxious?

 Northwestern scientists have identified, for the first time, a specific group of neurons -- cells in the brain -- that appear to contribute to anxiety caused by cannabinoid drugs, particularly when those drugs are combined with stressful conditions. Cannabinoids are a category of substances that includes THC, the main psychoactive ingredient in cannabis.

To investigate how cannabinoids influence fear and anxiety, researchers exposed mice to a threatening smell derived from fox urine. Before encountering the odor, the animals were given either a placebo or a synthetic cannabinoid drug.

Mice that received the cannabinoid froze more frequently and spent less time exploring the predator scent. Researchers traced these anxiety related behaviors to increased activity in a small population of brain cells known as somatostatin neurons. These neurons are located in the central amygdala, an area of the brain involved in processing fear and stress.

When the researchers genetically silenced the somatostatin neurons, the mice that received the cannabinoid became less likely to avoid the predator odor. The result suggested that these cells play an important role in producing the anxious response.

"The results of this study could explain why a good trip can turn bad pretty quickly if people consume too much cannabis or the situation they are in turns stressful or scary," said study senior author Dr. Sachin Patel, chair of psychiatry and behavioral sciences at Northwestern University Feinberg School of Medicine.

The study was published on Oct. 2 in Nature Communications.

Tracking the Brain During a Threat

Patel and his colleagues gave mice several different doses of the synthetic cannabinoid and measured their reactions to the predator odor. The researchers recorded how much time the animals spent near the scent and whether they responded by freezing or fleeing.

At the same time, the team monitored activity inside the brain by implanting a small microscope into the mice's brain.

Researchers also studied brain tissue to determine how cannabinoids changed communication between neurons. Their experiments showed that the drug weakened a natural brain mechanism that normally acts as a "brake" on somatostatin neurons. With that restraint reduced, the neurons became more active.

"Higher doses of cannabinoids and environmental stress worked together to synergistically release the 'brake' on the central amygdala, which in turn drove excessive anxiety," Patel explained.

Why Cannabis and Anxiety Matter

Cannabis use in the U.S. has steadily increased in recent years. At the same time, emergency department visits involving adverse effects from the drug have also risen.

Previous studies have found an association between cannabis use and a higher long term risk of anxiety. Anxiety and mood disorders are also on the rise globally.

"Understanding how cannabis affects brain function to generate its psychoactive effects could ultimately reveal new ways to counteract negative consequences should they arise in some people," Patel said.

The researchers believe the findings may also have relevance beyond cannabis related side effects. Patel said the same neurons could potentially represent a broader target for understanding or reducing anxiety.

"Suppressing the activity of somatostatin neurons in the central amygdala could represent a final pathway for reducing anxiety symptoms, not just in the context of cannabis side effects," he explained.

Other Northwestern co-authors are Farhana Yasmin, Saptarnab Naskar, Danyal Zaidi, Isaac Kandil, Michelle Kwon and Dr. Luis Rosas-Vidal.

The study is titled, "Cannabinoid Modulation of Central Amygdala Population Dynamics During Threat Investigation." It was supported by the National Institutes of Health (grants MH100785 and K08 MH126166) and the Brain & Behavior Research Foundation's Young Investigator Awards.

Source: ScienceDaily

Saturday, 14 November 2026

Scientists uncover 3 key brain pathways linked to lasting depression relief

 Scientists at Mount Sinai have identified three important brain connections associated with long-term improvement in patients receiving deep brain stimulation (DBS) for severe depression that has not responded to conventional treatments. The discovery could help researchers make this experimental therapy more precise and effective.

Published October 1 in the American Journal of Psychiatry, the research examined the largest group of patients assembled across multiple independent cohorts to date who had received subcallosal cingulate deep brain stimulation (SCC DBS) for treatment-resistant depression.

The researchers found that lasting improvements were consistently associated with electrical stimulation reaching three specific white matter pathways: the cingulum bundle, forceps minor, and medial uncinate fasciculus/ventral amygdalofugal pathways.

These findings strengthen the case for using detailed maps of the brain's connections to determine exactly where electrodes should be implanted, rather than choosing their positions based primarily on anatomical landmarks. Known as connectome-based targeting, this strategy has already helped shape the ongoing Abbott TRANSCEND clinical trial, a randomized, controlled study that uses individualized brain connectivity maps to guide SCC DBS treatment.

"This study underscores the importance of individualized surgical targeting for achieving optimal outcomes with deep brain stimulation for depression," said Helen Mayberg, MD, Mount Sinai Professor in Neurotherapeutics and founding Director of the Nash Family Center for Advanced Circuit Therapeutics at the Icahn School of Medicine at Mount Sinai. "In any randomized controlled trial of a neuromodulation treatment, precise lead placement and confirmation that the intended brain target has been engaged are essential first steps. We still have much to learn about which patients are most likely to benefit from stimulation of this particular target, but developing imaging-based signatures that can match patients to their optimal treatment remains a central goal of our research."

How Deep Brain Stimulation Targets Severe Depression

For people with treatment-resistant depression, standard therapies have failed to provide adequate relief. Researchers are investigating deep brain stimulation as a possible treatment for individuals living with severe, persistent symptoms.

The procedure involves surgically placing electrodes inside the brain to deliver controlled electrical signals to circuits involved in depression. However, positioning the electrodes correctly remains one of the greatest challenges.

Electrical stimulation does not simply affect the brain tissue closest to an implanted electrode. It can also influence larger networks through the white matter pathways that connect different brain regions. As a result, two patients with electrodes implanted in nearly identical locations may experience very different outcomes depending on which connections are actually stimulated.

Earlier research from Mount Sinai and Emory University helped establish the importance of these networks. In studies published between 2014 and 2023 in Biological Psychiatry, Molecular Psychiatry, and Nature, the teams identified white matter pathways associated with successful SCC DBS treatment and developed a method for planning electrode placement using brain connectivity maps.

The latest investigation sought to determine whether those connections were also important in patients treated at other research centers. Scientists also wanted to understand whether differences in the pathways reached by stimulation could help account for patients who did not benefit.

Three Brain Connections Linked to Lasting Improvement

To investigate, the researchers examined information from several clinical studies, including the BROADEN trial and a patient cohort at the University of Toronto, where SCC DBS was originally developed.

They used computer models of the electrical fields generated by implanted electrodes alongside maps of brain connectivity. This allowed them to estimate which pathways received stimulation and compare those patterns across different patient groups.

The results showed a consistent relationship between sustained improvement and stimulation of the cingulum bundle, forceps minor, and medial uncinate fasciculus/ventral amygdalofugal pathways.

One finding was especially notable. Across the study sites, patients who had not responded to treatment after two years showed a lack of stimulation engagement with the left cingulum bundle.

The researchers did not investigate whether moving electrodes to reach this pathway would improve those patients' symptoms. Nevertheless, the pattern offers a possible explanation for why apparently similar electrode placements can produce different results. An electrode might be positioned in the correct general region but still fail to activate all the connections associated with lasting improvement.

Source: ScienceDaily

Friday, 13 November 2026

Yale scientists discover how stress changes the brain to make memories stronger

 Stress does more than influence how we feel. It can also change what we remember, particularly when an experience is emotionally intense or personally meaningful. Scientists have long known that cortisol, a hormone released during stressful situations, can strengthen emotional memories. What has been less clear is exactly how this happens inside the brain.

Researchers at Yale University have now uncovered important clues. Their study reveals that cortisol strengthens emotional memories by changing how brain networks involved in emotion and memory function and communicate with one another. The findings offer a deeper understanding of why certain experiences leave such powerful impressions while others quickly fade.

"We all experience stress, and my lab is interested in understanding how stress can be helpful," said corresponding author Elizabeth Goldfarb, an assistant professor of psychiatry at Yale School of Medicine and of psychology in the Faculty of Arts and Sciences.

The findings were published in the journal Science Advances.

How Stress Hormones Influence Memory

Previous research involving both humans and rodents has shown that stress and cortisol can improve memory for emotional events. Scientists also know that certain brain regions, including the amygdala, play an essential role in this process. The amygdala is particularly important for processing emotions and identifying experiences that may be significant.

However, understanding precisely how cortisol strengthens memories has been challenging. Many brain regions participate in several mental functions, making it difficult to determine whether the hormone is influencing emotional responses, memory formation, or both.

"Forming memories for emotional experiences involves different processes in the brain: first, perceiving an experience as emotional or intense, and second, encoding that experience into long-term memory," said Goldfarb, who is also a member of Yale's Wu Tsai Institute, an interdisciplinary research initiative that explores cognition.

The researchers wanted to examine these processes separately to determine how cortisol affects the brain's ability to recognize emotional significance and preserve an experience as a lasting memory.

Watching the Brain Form Emotional Memories

To investigate, the Yale team conducted an experiment in which participants took a pill containing either hydrocortisone, a form of cortisol, or an inactive placebo. They then viewed a series of pictures while undergoing functional MRI (fMRI) scanning.

This imaging technique measures changes in blood flow and oxygen levels associated with brain activity, allowing researchers to identify which areas of the brain are more active during different tasks.

As participants examined the pictures, they reported their emotional reactions to each image. The following day, researchers tested how well they remembered what they had seen.

Each person completed the experiment twice, once after receiving hydrocortisone and once after receiving the placebo. The study used a double blind design, meaning neither the participants nor the experimenter knew which substance had been administered during a particular session.

This approach allowed the scientists to compare how the same person's brain responded with and without the additional cortisol.

A Five-Second Look at Brain Network Activity

One of the study's most important advances came from the way researchers analyzed the brain scans.

Scientists often study a measurement called functional connectivity, which describes how closely activity in different parts of the brain fluctuates together. When two regions show synchronized patterns of activity, it can indicate that they are participating in related processes.

Traditionally, examining these relationships requires several minutes of brain imaging data. The Yale team instead analyzed functional connectivity during individual trials lasting only around five seconds.

Using these brief snapshots, the researchers tested whether patterns of brain activity could predict two different outcomes: how emotionally intense participants found a picture and whether they would remember that picture the following day.

The approach worked for both. By identifying patterns associated with emotional intensity and memory formation separately, the scientists were able to examine how cortisol influenced each network and the interactions between them.

This gave the researchers a more detailed picture of the changing brain activity associated with emotional memory formation.

Source: ScienceDaily

Thursday, 12 November 2026

Breakthrough PTSD treatment achieves 68% remission rate in clinical trial

 A new approach to treating post-traumatic stress disorder (PTSD) has received FDA clearance, offering a personalized alternative for people who have not found sufficient relief through existing treatments. Developed by California-based Wave Neuroscience in collaboration with researchers at the Texas A&M Health Institute of Biosciences and Technology, the technology uses brain activity measurements to guide targeted magnetic stimulation.

Early clinical trial findings have been encouraging. According to Wave Neuroscience, patients experienced a 52% reduction in PTSD symptoms, while 68% achieved remission. The full findings are still being prepared for public release, but researchers believe the technology could significantly expand treatment options for millions of people.

The need for more effective PTSD care is substantial. In the United States, approximately 17.5 veterans die by suicide each day, and about 7% of veterans receive a PTSD diagnosis annually.

PTSD can develop after traumatic experiences such as military combat, serious accidents, natural disasters, or violence. An estimated 6% of Americans will experience PTSD during their lifetime, with higher rates among women and veterans.

Why Current PTSD Treatments Are Not Enough

Since PTSD was formally recognized as a diagnosis in 1980, treatment has largely centered on psychotherapy and medications known as selective serotonin reuptake inhibitors (SSRIs), including sertraline and fluoxetine.

Although these approaches can help, many patients continue to experience symptoms despite receiving treatment.

A 2020 review of PTSD medications found that patients reported improvements ranging from 6.8 to 10.1 points on symptom assessments. However, remission rates reached only 10.9% at most.

Wave Neuroscience reported substantially stronger preliminary outcomes in its clinical trial. Erik Won, DO, the company's chief medical officer, described the results as a major advance over previously reported medication outcomes.

“In comparison to that study, our FDA trial reported a 52% reduction in symptoms, so more than a four-fold increase in efficacy,” Won said. “And more importantly, we saw 68% remission in our clinical trial. So, it’s really a quantum change, an inflection point in what we can offer to patients. From a clinical care perspective, that’s really meaningful.”

These findings are promising, although the results come from different studies and should not be interpreted as a direct comparison of treatment effectiveness.

How Personalized Brain Stimulation Works

The newly cleared system uses Magnetic e-Resonance Therapy (MeRT), a technology that combines measurements of brain activity with targeted magnetic stimulation

First, an electroencephalogram (EEG) records the brain's electrical signals. This information helps guide a personalized treatment plan using transcranial magnetic stimulation, or TMS.

During TMS, a coil positioned against the scalp delivers magnetic pulses that stimulate brain activity. The technique has already been used for other psychiatric conditions, including treatment-resistant depression.

What distinguishes MeRT is its use of an AI-assisted algorithm to customize stimulation protocols based on each patient's brain activity rather than relying on a standardized approach.

“Transcranial magnetic stimulation, or TMS, was previously FDA cleared for treatment-resistant depression,” Won said. “By adding an augmented AI derived multivariate algorithm, we were able to personalize protocols that received FDA clearance for post-traumatic stress disorder, which should open up market access to about 13 million people who may be struggling with PTSD.”

Dr. Kenneth S. Ramos, a physician-scientist at Texas A&M Health with extensive experience in precision medicine, helped guide the research.

His work focuses on adapting medical care to the characteristics of individual patients instead of assuming that everyone will respond to the same treatment.

“Most clinical interventions for the treatment of PTSD do not work very well,” Ramos said. “So, this is a huge area where identifying interventions that could hopefully add quality of life to the people impacted by this disorder would be tremendously impactful.”

Wave Neuroscience CEO Fred Walke said Ramos was a natural fit for the project because of his expertise in personalized medicine.

Targeting PTSD With Greater Precision

Conventional TMS generally follows treatment protocols that are less individualized. MeRT builds on the same underlying technology but adjusts treatment according to the patient's specific brain activity.

Ramos emphasized that even small biological differences between people can have major implications for medical care. Humans are approximately 99.9% genetically alike, yet the remaining 0.1% contributes to differences that can influence how individuals respond to treatment.

Source: ScienceDaily

Wednesday, 11 November 2026

Scientists discover why chronic back pain feels so personal

 For people living with chronic back pain, even a simple movement can trigger a sudden surge of pain. Now, scientists have discovered that these painful episodes activate a surprising part of the brain, one closely connected to our sense of identity and how we think about ourselves.

Researchers at UC San Diego School of Medicine found that movement-triggered pain in people with chronic low back pain (cLBP) activates a brain network that normally becomes less active during ordinary pain. The discovery suggests that persistent back pain may become deeply intertwined with a person's sense of self, potentially helping explain why conventional pain treatments often provide limited relief.

According to the World Health Organization, low back pain is the leading cause of disability worldwide. When pain persists for more than 12 weeks, it is considered chronic. For many patients, everyday movements can provoke sudden flare-ups that make an already difficult condition even harder to manage.

Although the brain plays a central role in how pain is experienced, researchers have struggled to identify the precise brain circuits responsible for pain triggered by movement.

Chronic Back Pain Activates the Brain's Sense of Self

The new study, published on October 5, 2026, in the British Journal of Anaesthesia, identified an unexpected response involving the brain's Default Mode Network (DMN).

Sometimes called the "self network," the DMN consists of interconnected regions in the frontal, parietal, and temporal lobes. These areas are especially active when our attention turns inward, such as when we reflect on personal experiences, think about our identity, or consider our thoughts and emotions. In contrast, the network generally becomes less active when we direct our attention toward something happening around us.

The researchers discovered that sudden back pain caused by movement switched this network on rather than off. This unusual response suggests that chronic pain involves more than the processing of physical sensations. It may also engage the brain systems that shape how people experience themselves.

The findings could help researchers understand why treatments that focus primarily on suppressing pain symptoms do not always work well for chronic low back pain. They also raise the possibility that targeting the DMN could offer a different approach to treatment.

Brain Scans Reveal a Surprising Difference Between Chronic and Acute Pain

To investigate what happens in the brain during a pain flare, the researchers recruited 114 patients with chronic low back pain.

Each participant completed a "leg raise test," a standard clinical procedure used to provoke back pain. During the test, researchers monitored changes in brain blood flow using a specialized functional MRI method called arterial spin labeling. This technique allows scientists to track patterns of brain activity by measuring blood flow without relying on an injected contrast agent.

The team also examined how participants responded to a separate painful stimulus. They applied a harmless but uncomfortable heat sensation to the calf, similar to the brief pain someone might experience when accidentally touching a hot stove.

Comparing these two situations revealed a striking difference.

When movement triggered a flare of chronic back pain, the DMN became more active. However, when participants experienced the painful heat stimulus, the same network became less active, following the brain's typical response to acute pain.

The researchers also identified several other important patterns:

  • Patients with more severe chronic back pain showed stronger connections between the DMN and the primary somatosensory cortex, a brain region responsible for processing physical sensations, including signals from the back.
  • Greater pain intensity during the leg raise test was associated with increased activity in brain regions involved in sensation and movement.
  • Increases in heart rate during the test reliably reflected the intensity of the pain flare.

Together, these findings provide new evidence that chronic pain flares involve brain processes associated with personal identity, not just the physical experience of pain.

Why the Brain Reacts Differently to Chronic Pain

During ordinary acute pain, the brain generally reduces activity in the DMN so it can concentrate on the immediate source of danger. This response helps shift attention away from internal thoughts and toward an external threat.

But the UC San Diego researchers found that movement triggered chronic back pain produced the opposite effect.

"In every pain study, when you're experiencing pain, the DMN deactivates," said corresponding author Fadel Zeidan, PhD, professor in the Department of Anesthesiology, endowed professor at the Sanford Institute for Empathy and Compassion, and director of the Pain Health and Mindfulness Laboratory at UC San Diego School of Medicine. "What we show for the first time ever is that when you have a pain flare, it turns on instead. You start to identify the experience with who you are."

Source: ScienceDaily

Tuesday, 10 November 2026

Magic mushrooms rewire the brain in a way scientists didn't expect

 A new study from the University of California, Santa Cruz, has revealed how psilocybin, the psychedelic substance found in "magic mushrooms," changes the brain by reorganizing connections between nerve cells. The findings could eventually help scientists develop treatments for mental health conditions that capture some of psilocybin's potential benefits without producing hallucinations.

The research, published October 15 in Nature Neuroscience, found that psilocybin rapidly encourages brain cells to form new connections and helps those connections mature. At the same time, it promotes the removal of certain older connections, suggesting that its effects involve more than simply increasing communication between neurons.

Experiments in mice also revealed something especially intriguing. The researchers were able to separate the cellular changes responsible for this rewiring from a behavioral response commonly associated with psychedelic effects. This suggests that some of psilocybin's effects on brain structure may be achievable without the hallucinations typically associated with the drug.

The discovery could provide a foundation for developing medications that enhance the brain's ability to adapt and reorganize itself, a property known as neuroplasticity. Such treatments might eventually offer new approaches for depression, post-traumatic stress disorder (PTSD), and other psychiatric conditions.

The team also identified a particular group of neurons in the cerebral cortex that plays an essential role in psilocybin's effects on brain connections. Importantly, the researchers discovered that the drug does not affect every brain in the same way. Its influence depends partly on whether the brain has previously experienced chronic stress.

"I consider this work a major advance, particularly in our understanding of how psilocybin reshapes neural circuits and its potential implications for treating mental disorders," said senior author Yi Zuo, professor of molecular, cell, and developmental biology at UC Santa Cruz.

Why Scientists Are Taking a New Look at Psychedelics

Scientific interest in psychedelic drugs has changed dramatically over the past century. During the middle of the 20th century, substances such as psilocybin and LSD attracted attention from Western researchers because of their powerful effects on perception, consciousness, and mood.

Early studies suggested these compounds might have applications in psychiatric treatment. However, scientific investigations slowed substantially after the United States passed the Controlled Substances Act in 1970, which imposed strict restrictions on these substances.

In recent years, researchers have renewed their interest in psychedelics, particularly their ability to produce rapid and potentially lasting changes in brain function.

Scientists sometimes describe these compounds as "psychoplastogens" because they can stimulate neuroplasticity after a single dose. Neuroplasticity refers to the brain's capacity to change its structure and activity by forming, strengthening, reorganizing, or removing connections between neurons.

This property is particularly interesting for mental health treatment because conditions such as depression can involve disruptions in the circuits responsible for regulating mood, emotions, and behavior.

The U.S. Food and Drug Administration (FDA) has previously recognized the therapeutic potential of psychedelic research by granting Breakthrough Therapy designations to substances including psilocybin and MDMA. These designations are intended to accelerate the development and review of promising treatments for serious medical conditions.

In September 2026, the FDA took another step toward evaluating psychedelic treatments by organizing a public hearing titled "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs."

Experts discussed how healthcare professionals administering psychedelic treatments should be qualified, how potential risks could be managed through Risk Evaluation and Mitigation Strategy (REMS) programs, and how future clinical trials should be designed.

As regulators examine ways psychedelic treatments might eventually become part of mainstream healthcare, researchers are increasingly focused on understanding exactly what these substances do to the brain. Identifying the cellular mechanisms behind their effects could help scientists develop treatments that are both effective and safer to administer.

Watching Psilocybin Rewire the Brain

To investigate how psilocybin changes brain structure, the UC Santa Cruz team used an advanced imaging method called two-photon microscopy.

This technology allows scientists to observe extremely small structures inside living tissue with remarkable detail. Using it, the researchers followed individual connections on neurons in living mice over several weeks, allowing them to see how those structures changed after psilocybin treatment.

Source: ScienceDaily

Monday, 9 November 2026

Scientists find surprisingly little evidence that medical cannabis helps you sleep

 A major new scientific review is raising questions about whether medical cannabis actually helps people with insomnia. Despite growing interest in cannabis as a sleep treatment, researchers found that the available evidence is too weak to reliably determine whether it improves sleep quality, sleep duration, or how well people function during the day.

Insomnia affects millions of people and can make it difficult to fall asleep, remain asleep throughout the night, or wake up feeling rested. Beyond the frustration of sleepless nights, the condition can seriously disrupt daily life and increase the likelihood of developing anxiety or depression.A major new scientific review is raising questions about whether medical cannabis actually helps people with insomnia. Despite growing interest in cannabis as a sleep treatment, researchers found that the available evidence is too weak to reliably determine whether it improves sleep quality, sleep duration, or how well people function during the day.

Insomnia affects millions of people and can make it difficult to fall asleep, remain asleep throughout the night, or wake up feeling rested. Beyond the frustration of sleepless nights, the condition can seriously disrupt daily life and increase the likelihood of developing anxiety or depression.

Treatments for insomnia include cognitive behavioral therapy, which helps people change thoughts and habits that interfere with sleep, as well as medications such as antidepressants and antipsychotics. However, these approaches do not work equally well for everyone, fueling interest in alternative options.

Medical cannabis has attracted particular attention because of its potential to improve sleep. Unlike recreational cannabis, regulated medical products typically contain carefully measured amounts of THC and CBD, two compounds found in cannabis, and are administered as tablets, sprays, or oils. Despite its growing popularity, scientists have continued to debate whether cannabis offers meaningful benefits for people with insomnia.

Major Review Finds Little Evidence of Sleep Benefits

To investigate, researchers from The Cochrane Associate Centre at the Universidad Hospital Italiano de Buenos Aires and the University of Manitoba examined nine clinical studies involving 537 adults between the ages of 18 and 76 who were receiving treatment for insomnia.

Most of the studies involved people with primary insomnia, meaning their sleep problems were not attributed to another medical condition. Eight trials compared regulated medical cannabis with a placebo, an inactive treatment used to measure whether a therapy produces genuine benefits. The remaining trial compared cannabis with amitriptyline, an antidepressant that is sometimes used to treat sleep problems.

Across the placebo comparisons, medical cannabis produced little or no clinically meaningful improvement in sleep quality, satisfaction with sleep, total hours slept, or daytime functioning.

The researchers also identified potential drawbacks. Participants who received medical cannabis were substantially more likely to experience mild side effects, including dizziness and dry mouth, than those given a placebo. However, this finding came from a relatively small number of studies, limiting confidence in the result.

There was some indication that medical cannabis might improve overall quality of life. Yet the evidence supporting this possibility was highly uncertain. When the findings were combined, the results were consistent with outcomes ranging from a slight decline in quality of life to a substantial improvement.

"The main message is that the research currently available is not sufficient to reliably answer whether medical cannabis helps people with insomnia," says Dr. Lucia Varela, lead author of the study from the University of Manitoba, Canada. "This does not mean that medical cannabis is ineffective. It means that, based on the evidence we have, we cannot draw reliable conclusions about its effectiveness for insomnia in the general population."

Why Scientists Remain Uncertain About Cannabis and Insomnia

One of the biggest problems was the quality of the research itself. The reviewers rated their confidence in the available evidence as low or very low, citing small study populations, conflicting findings, and potential bias in how the trials were conducted.

Another challenge was the lack of consistency between studies. Researchers tested different medical cannabis products, making it difficult to directly compare their results or determine whether particular formulations might work better than others.

The studies were also relatively short. The longest followed participants for just 12 weeks, leaving major unanswered questions about whether medical cannabis could provide lasting sleep benefits or produce additional effects with prolonged use.

More Research Is Needed Before Cannabis Can Be Recommended

The researchers also cautioned that the study participants did not adequately represent the broader population of people living with insomnia.

Women accounted for nearly three-quarters (72.66% of participants), and the research was heavily weighted toward younger adults. As a result, it remains unclear whether the findings would apply equally to men, older individuals, or people whose insomnia occurs alongside other medical conditions.

Taken together, these limitations mean that the existing research cannot establish whether medical cannabis is an effective insomnia treatment. The authors emphasize that larger, more rigorous clinical trials are needed before it can be confidently recommended for improving sleep."The main message is that the research currently available is not sufficient to reliably answer whether medical cannabis helps people with insomnia," says Dr. Lucia Varela, lead author of the study from the University of Manitoba, Canada. "This does not mean that medical cannabis is ineffective. It means that, based on the evidence we have, we cannot draw reliable conclusions about its effectiveness for insomnia in the general population."

Why Scientists Remain Uncertain About Cannabis and Insomnia

One of the biggest problems was the quality of the research itself. The reviewers rated their confidence in the available evidence as low or very low, citing small study populations, conflicting findings, and potential bias in how the trials were conducted.

Another challenge was the lack of consistency between studies. Researchers tested different medical cannabis products, making it difficult to directly compare their results or determine whether particular formulations might work better than others.

The studies were also relatively short. The longest followed participants for just 12 weeks, leaving major unanswered questions about whether medical cannabis could provide lasting sleep benefits or produce additional effects with prolonged use.

More Research Is Needed Before Cannabis Can Be Recommended

The researchers also cautioned that the study participants did not adequately represent the broader population of people living with insomnia.

Women accounted for nearly three-quarters (72.66% of participants), and the research was heavily weighted toward younger adults. As a result, it remains unclear whether the findings would apply equally to men, older individuals, or people whose insomnia occurs alongside other medical conditions.

Taken together, these limitations mean that the existing research cannot establish whether medical cannabis is an effective insomnia treatment. The authors emphasize that larger, more rigorous clinical trials are needed before it can be confidently recommended for improving sleep.

Source: ScienceDaily